Transcept Stock Hits New 52-Week High (TSPT)

NEW YORK ( TheStreet) -- Transcept Pharmaceuticals (Nasdaq: TSPT) hit a new 52-week high Monday as it is currently trading at $11.92, above its previous 52-week high of $11.88 with 407,807 shares traded as of 3 p.m. ET. Average volume has been 382,600 shares over the past 30 days.

Transcept has a market cap of $110.7 million and is part of the health care sector and drugs industry. Shares are up 42% year to date as of the close of trading on Thursday.

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience.

TheStreet Ratings rates Transcept as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. You can view the full Transcept Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

4 Stocks Under $10 Making Big Moves

5 Stocks Under $10 Set to Soar

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Stocks Under $10 Making Big Moves

Transcept Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript